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ABSTRACT
A population-based nationwide surveillance of antibiotic resistance associated with invasive pneumo-
coccal disease (IPD) in children and adolescents (aged <16 years) was performed in Germany between
1997 and 2004. In total, 1517 isolates were collected, of which 5.1% and 1.1% were intermediately- or
fully-resistant, respectively, to penicillin G. During the 8-year study period, an increase in resistance to
both penicillin G and erythromycin A was observed, and the frequency of isolates exhibiting reduced
susceptibility to penicillin G or erythromycin A increased from 1.4% and 11.1%, respectively, in 1997, to
8.7% and 29.0%, respectively, in 2004. Among the penicillin non-susceptible pneumococcal isolates,
serotypes 14 (24.5% of isolates), 23F (16.0%) and 6B (16.0%) were found most frequently. Multilocus
sequence typing of 58 (62%) penicillin G non-susceptible isolates revealed that sequence type (ST) 156
(Spain9V-3 clone) and its single-locus variant ST 557 were widespread in Germany. Moreover, 17 new
penicillin G non-susceptible STs were deﬁned for the ﬁrst time. The study illustrated the genetic
heterogeneity of antibiotic-resistant pneumococcal isolates in Germany.
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INTRODUCTION
Streptococcus pneumoniae continues to be a signi-
ﬁcant cause of morbidity and mortality in humans
[1]. The worldwide increase in antibiotic resist-
ance has become a serious problem within the last
20 years [2]. In Europe, rates of resistance to
penicillin G vary substantially among countries.
For example, high rates of penicillin G resistance
have been reported from France and Spain,
whereas signiﬁcantly lower resistance rates are
documented in Germany, Austria and Switzer-
land [3–5].
Among children aged <2 years, the incidence
of invasive pneumococcal disease (IPD) ranges
from c. 14 cases ⁄ 100 000 in Germany and The
Netherlands to >90 cases ⁄ 100 000 in Spain. The
vulnerability of children to S. pneumoniae can
also be demonstrated by the high rate of
sequelae (>20% in Germany) and the high
mortality rate (7.5%) for pneumococcal menin-
gitis. Furthermore, in addition to penicillin G,
antibiotic resistance among S. pneumoniae iso-
lates is increasing in Europe, particularly in
France, Spain and eastern European countries,
whereas Germany and northern European coun-
tries appear to be less affected. A seven-valent
pneumococcal conjugate vaccine (7vPCV), which
has been shown to be highly efﬁcacious in
preventing IPD among infants in the USA, was
licensed for use in Europe during 2001. It is
expected that widespread use of the vaccine will
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reduce the incidence of invasive pneumococcal
disease and the levels of pneumococcal resist-
ance signiﬁcantly [6].
Multilocus sequencing typing (MLST) is a
molecular typing method that provides unambig-
uous data concerning seven housekeeping genes
that can be transmitted electronically [7,8]. MLST
has the major advantage that any laboratory can
compare the sequences of the seven loci of isolates
with those in a central database (http://www.
mlst.net), and thereby obtain the corresponding
allelic proﬁle. The present study used this tech-
nique to analyse the genetic relatedness of peni-
cillin G-resistant S. pneumoniae isolates from a




The study was based on active surveillance in Germany of IPD
in the population aged <16 years. Children were enrolled in
the study if they had been admitted to a paediatric hospital
and if S. pneumoniae had been isolated from at least one culture
of blood, cerebrospinal ﬂuid or a sample from any other
normally sterile body site. Cases were identiﬁed through two
independent surveillance systems: a hospital-based system
(including all paediatric hospitals in Germany) and a labora-
tory-based system (including all microbiological laboratories
cooperating with paediatric hospitals). The paediatric hosp-
itals and microbiological laboratories were asked, on a
monthly basis, for data concerning cases of IPD; case reports
from both systems were validated by questionnaires. The
participating laboratories were requested to send pneumo-
coccal isolates to the German National Reference Centre for
Streptococci (NRCS), where the species diagnosis was con-
ﬁrmed and serotyping and antimicrobial susceptibility testing
were performed [9].
Susceptibility testing
MICs were determined using the broth microdilution
method recommended by the CLSI [10]. Microtitre plates
containing penicillin G, cefotaxime, erythromycin A and
clindamycin were used with cation-adjusted Mueller–Hinton
broth (Oxoid, Wesel, Germany) containing lysed horse blood
(Oxoid) 5% v ⁄v and a ﬁnal inoculum of 5 · 105 CFU ⁄mL.
MICs were determined following incubation at 35C for 24 h
in ambient air. S. pneumoniae ATCC 49619 was used as a
control strain. Current CLSI interpretive criteria were used
to deﬁne antimicrobial resistance [10]. Isolates were stored at
)70C on porous beads (Microbank; Mast Diagnostics,
Rheinfeld, Germany).
Serotyping
Pneumococcal isolates were serotyped by Neufeld’s Quellung
reaction using type and factor sera provided by the Statens
Serum Institut (Copenhagen, Denmark).
MLST
A subgroup (n = 58) of all (n = 94) penicillin G non-susceptible
isolates was selected by randomisation of the sequential
database entry number of penicillin G non-susceptible isolates
received between 1997 and 2004. MLST was performed as
described previously. In brief, internal fragments of the aroE,
gdh, gki, recP, spi, xpt and ddl genes were ampliﬁed by PCR
from chromosomal DNA with the primer pairs described by
Enright and Spratt [8]. The alleles at each of the seven loci
provide the allelic proﬁle for each isolate, and also deﬁne their
sequence type (ST). Allelic proﬁles are reported as the alleles at
each of the seven loci, in the order aroE, gdh, gki, recP, spi, xpt
and ddl. The allelic proﬁles of the German isolates were
compared with each other and with other isolates in the
pneumococcal MLST database (http://www.mlst.net). Addi-
tional MLST data for control strains were also obtained from
the database.
Phylogenetic analysis
For phylogenetic analysis, the sequences of the aroE, gdh, gki,
recP, spi and xpt gene fragments were concatenated using the
concatenation tool available at http://www.mlst.net. As
recommended, the ddl gene was excluded from analysis, since
it appears to be highly variable in penicillin-resistant isolates
[11]. The clonal relatedness of the 37 different MLSTs, as well
as the relatedness of these 37 MLSTs to all other MLSTs in the
database, was investigated using the eBURST program
(http://spneumoniae.mlst.net/eburst/) [12]. The concaten-
ated sequences (2715 bp) were also aligned with the multiple
sequence alignment tool ClustalW. The PUZZLE program was
used to create a phylogenetic tree from the multiple alignment
by maximum-likelihood analysis [13]. All programs were
obtained from the HUSAR program package of the Biocom-
puting Service Group (http://genius.dkfz-heidelberg.de).
Statistical analysis
Linear regression analysis was performed using SPSS v.14.0
(SPSS Inc., Chicago, IL, USA). Chi-square tests were performed
using the chi-square webtool of Georgetown University
(http://www.georgetown.edu/). All serotypes represented
by four or fewer non-susceptible isolates were grouped
together in the ‘other’ category. In addition, the resistance
ratio was calculated by dividing the number of non-susceptible
isolates of each serotype by the total number of isolates of the
same serotype. This resistance ratio can generate values
between 0% and 100%; if there is no association between
serotype and susceptibility to penicillin, all resistance ratio
values should be similar.
RESULTS
Between 1997 and 2004, 1517 isolates of S. pneu-
moniae were collected consecutively by 188 of 245
laboratories participating in the study. These
isolates were from blood (n = 966; 63.7%), cere-
brospinal ﬂuid (n = 505; 33.3%) and other nor-
mally sterile body sites (n = 46; 3.0%). Antibiotic
resistance data are summarised in Table 1. Of the
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1517 isolates, 94 showed reduced susceptibility to
penicillin G (6.2%), of which 17 (1.1%) were
highly-resistant. Erythromycin A and clindamy-
cin resistance was observed in 23.7% and 5.9% of
isolates, respectively. During the study period, a
signiﬁcant increase in both penicillin G
(MIC ‡2 mg ⁄L; p 0.008) and erythromycin A
(MIC ‡1 mg ⁄L; p 0.002) resistance was observed.
The rate of penicillin G non-susceptible isolates
(MIC ‡0.1 mg ⁄L; p 0.073) rose from 1.4% in 1997
to 8.7% in 2004. It is of note that 3.5% of strains
were penicillin G-resistant (‡2 mg ⁄L) in 2004,
whereas no resistant isolates were obtained in
1997.
Serotyping of the penicillin non-susceptible
isolates identiﬁed 13 different serotypes, with
serotypes 14 (24.5%), 6B (16.0%) and 23F (16.0%)
being predominant. The coverage of the seven-
valent pneumococcal conjugate vaccine was 77%
for penicillin non-susceptible isolates (Table 2).
Comparison of the calculated resistance ratios for
all serotypes showed that the values differed
enormously, implying that there is an association
between serotype and penicillin resistance
(Table 2). Analysis using chi-square tests showed
that serotype and antibiotic susceptibility were
associated at a highly signiﬁcant level (chi-square
66.6; degree of freedom 6; p £0.001).
MLST was performed on 58 randomly selected
penicillin G non-susceptible isolates and identi-
ﬁed 38 different STs. Interestingly, one serotype
14 isolate (RKI 1158) showed an atypical ST, with
unusual mutations in all seven alleles investi-
gated. ST 557 (a single-locus variant of the
Spain9V-3 clone; 8.6% of isolates) and the closely
related ST 156 (Spain9V-3 clone; 8.6%) were the
STs found most commonly among the group of 58
selected isolates (Table 3). The allelic proﬁles of 17
new penicillin G-resistant ‘German’ isolates are
listed in Table 4.
Table 1. Antibiotic resistance of
1517 Streptococcus pneumoniae iso-
lates from children with invasive
pneumococcal disease in Germany










n (%)Range 50% 90%
Penicillin G 0.008–4 0.016 0.03 1423 (93.8) 77 (5.1) 17 (1.1)
Cefotaxime 0.008–2 0.016 0.03 1505 (99.2) 9 (0.6) 3 (0.2)
Erythromycin A 0.016–32 0.06 8 1155 (76.1) 3 (0.2) 359 (23.7)
Clindamycin 0.016–32 0.06 0.125 1424 (93.9) 4 (0.3) 89 (5.9)
aBreakpoints according to the CLSI [10]: penicillin G, 0.12–1 mg ⁄L (I), ‡2 mg ⁄L (R); cefotaxime (meningitis), 1 mg ⁄L
(I), ‡2 mg ⁄L (R); cefotaxime (non-meningitis), 2 mg ⁄L (I), ‡4 mg ⁄L (R); erythromycin A, 0.5 mg ⁄L (I), ‡1 mg ⁄L (R);
clindamycin, 0.5 mg ⁄L (I), ‡1 mg ⁄L (R).
Table 2. Serotype distribution of 94 penicillin non-sus-
ceptible and 1423 penicillin-susceptible Streptococcus pneu-
moniae isolates from invasive pneumococcal disease in
Germany between 1997 and 2004
Serotype
Penicillin non-susceptible
n (%) of non-susceptible
isolates
Penicillin-susceptible






14 23 (24.5) 370 (26.0) 393 6
23F 15 (16.0) 98 (6.9) 113 13
6B 15 (16.0) 89 (6.3) 104 14
19F 11 (11.7) 89 (6.3) 100 11
19A 9 (9.6) 41 (2.9) 50 18
9V 8 (8.5) 49 (3.4) 57 14
9A 4 (4.3) 17 (1.2) 21 19
15A 2 (2.1) 13 (0.9) 15 13
29 1 (1.1) 0 1 100
15C 1 (1.1) 8 (0.6) 9 11
23B 1 (1.1) 3 (0.2) 4 25
6A 1 (1.1) 60 (4.2) 61 2
7F 1 (1.1) 91 (6.4) 92 1
NT 1 (1.1) 3 (0.2) 4 25
Rough 1 (1.1) 0 1 1
Others 0 492 (34.6) 492 0
Total 94 (100) 1423 (100) 1517 6
NT, non-typeable.
aNumber of non-susceptible isolates of a serotype ⁄ total number of isolates
belonging to the same serotype.
Table 3. Distribution of multilocus sequence types (STs)
of 58a penicillin non-susceptible Streptococcus pneumoniae
isolates in Germany between 1997 and 2004
ST Serotype Clone designationb n %
13 14 SLV England14-9 clone 1 1.7
15 14 SLV England14-9 clone 1 1.7
30 23F 1 1.7
63 15A Major global clone Sweden15A-25 1 1.7
81 9V, 23F PMEN global clone Spain23F-1 3 5.2
135 6B, 23F 3 5.2
142 23F 2 3.4
143 14 1 1.7
156 9A, 14 Pen-R Spain9V-3 clone 5 8.6
230 19A PMEN global clone ‘Clone 32’ 2 3.4
276 19A, 19F 2 3.4
277 6B, 23F 3 5.2
315 6B PMEN global clone Poland6B-20 3 5.2
334 9A SLV of penR Spain9V-3 clone 1 1.7
337 23F 1 1.7
339 19F 2 3.4
357 23F 1 1.7
359 23F 1 1.7
440 23F 1 1.7
550 14 1 1.7




aThe 58 isolates were selected randomly for MLST from among the total of 94
penicillin G non-susceptible isolates (see Table 3) and reﬂect the serotype distri-
bution among the 94 isolates.
bSee homepage of the Pneumococcal Molecular Epidemiology Network (PMEN)
(http://www.sph.emory.edu/PMEN).
Reinert et al. PNSP in Germany 365
 2007 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 363–368
An eBURST analysis of all isolates available in
the MLST database revealed that ﬁve isolates
(ST 143, ST 156, ST 334, ST 557 and ST 1557) were
members of a large clonal complex of 97 STs, of
which ST 156 is the predicted founder. Of the
clones described in the complex, ST 143, ST 156,
ST 334, ST 557 and ST 1557 were all found in the
present study. In addition, ST 30, ST 63, ST 81,
ST 135, ST 230 and ST 315 were also predicted
founders of clonal complexes. ST 142, ST 277,
ST 337, ST 339 and ST 359 were revealed to be
members of a clonal complex of 89 STs, with
ST 176 as the predicted founder. The other STs
found among the isolates in this study were
members of smaller complexes or existed as
singletons.
The above observations were conﬁrmed by
analysis of a dendrogram constructed using
maximum likelihood and the PUZZLE program
(data not shown). Analysis showed a large genetic
diversity of isolates and conﬁrmed that isolate
RKI 1158, with the atypical ST, was an outlier.
DISCUSSION
An increasing level of both penicillin G and
erythromycin A resistance was observed in the
present study of 1517 S. pneumoniae isolates from
children with IPD in Germany. During the 8-year
study period there was a greater than six-fold
increase in penicillin G resistance, and an almost
three-fold increase in macrolide resistance.
Although the development of resistance among
IPD isolates from children parallels that found in
adults and for non-invasive disease isolates in
Germany, the overall level of resistance among
children seems to be higher [5,14]. However, the
resistance level is still markedly lower than that
reported in southern and eastern European coun-
tries [4].
MLST is now used increasingly to analyse the
clonal relatedness of pneumococci [8,15–17]. The
present study is the ﬁrst in Germany to apply this
new technique to a relatively complete and
representative group of penicillin non-susceptible
pneumococcal isolates, collected as part of a
population-based nationwide surveillance pro-
gramme [9]. ST 557 (single-locus variant of
Spain9V-3 clone), the closely related ST 156
(Spain9V-3 clone) and ST 81 (Spain23F-1 clone)
were the predominant STs among these isolates.
Strains belonging to ST 156 were ﬁrst isolated
during the late 1980s in Spain, and are now
distributed worldwide (http://www.mlst.net). In
addition to being a carriage strain, ST 156 has also
been isolated from cases of bacteraemia and
meningitis in many countries, including Spain,
the UK, Denmark, Poland, Uruguay, Canada, The
Netherlands, France, the Czech Republic, Israel
and, recently, New Zealand [18]. Using eBURST
analysis, the results of the present study predicted
that ST 156 was the founder of a clonal group of
pneumococcal isolates prevalent in Germany.
However, Spratt et al. [19] suggest that ST 162 is
most probably the founder of this clonal complex,
since single-locus variants of ST 156 have been
greatly over-sampled.
In contrast, ST 557, which was the clone found
most commonly in the present study, has been
isolated previously only in Sweden (serotype 19F)
and Sri Lanka (serotype 6B, penicillin G-suscept-
ible). In addition, the Spain23F-1 clone, which
contributes signiﬁcantly to the worldwide spread
of penicillin and multiple antibiotic resistance in
S. pneumoniae [16,20–22], is also found in 5.2% of
penicillin non-susceptible invasive infections
among children in Germany. However, the pre-
sent study revealed 38 different clones among the
58 isolates examined, including 17 clones that
have been reported, to date, only in Germany.
Analyses of the clonal relatedness by eBURST and
construction of the phylogenetic tree by maxi-
mum-likelihood analysis highlighted the clonal
Table 4. New multilocus sequence types (STs) found
among 58 penicillin non-susceptible Streptococcus pneumo-
niae isolates from invasive pneumococcal disease in Ger-
man children between 1997 and 2004
Isolate ST Serotype
Alleles
aroE gdh gki recP spi xpt ddl
RKI 381 1087 19F 43 19 9 17 6 22 14
RKI 852 1190 6A 7 25 4 4 15 20 14
RKI 810 1444 23F 15 29 4 21 30 1 8
RKI 1205 1545 19F 2 5 36 16 1 21 14
RKI 372 1546 19A 2 13 2 5 6 26 8
RKI 627 1548 6B 2 22 4 5 27 4 14
RKI 830 1549 14 2 29 36 12 13 21 14
RKI 1110 1556 14 7 11 10 12 6 8 1
RKI 1117 1557 9A 7 11 10 17 6 8 14
RKI 1019 1565 19A 8 5 29 12 9 3 6
RKI 271 1576 15A 10 8 8 8 6 28 14
RKI 1157 1583 19F 15 16 19 15 6 20 71
RKI 176 1587 19A 8 19 2 17 25 5 168
RKI 662 1588 29 69 25 1 4 15 1 28
RKI 1083 1589 7F 8 9 2 1 6 1 167
RKI 1162 1590 6B 7 101 54 16 6 1 14
RKI 1158a ND 14 4V 20V 49V 40V 55V 51V 12V
aAtypical S. pneumoniae isolated from blood of a child aged 11 months. The isolate
was an optochin-susceptible and bile-soluble isolate of serotype 14, but showed
variations in all seven alleles.
V, variant; ND, no data.
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diversity of penicillin G non-susceptible S. pneu-
moniae isolates in Germany, and suggested that
these strains probably resulted from multiple
independent selection events. Such variability
seems to be typical for S. pneumoniae isolates,
with the exception of some countries, e.g., Spain,
where clones Spain9V-3 and Spain23F-1 constitute
nearly all antibiotic non-susceptible pneumococ-
cal isolates [15,17,23].
Pneumococcal conjugate vaccines now offer
the possibility of preventing IPD in children. A
seven-valent pneumococcal conjugate vaccine
(containing serotypes 4, 6B, 9V, 14, 18C, 19F
and 23F), which has been reported to be
immunogenic and efﬁcacious in infants, was
licensed in Europe during 2001 [6,24]. In Ger-
many, this vaccine is currently recommended
only for children with an increased risk of IPD,
and <10% of children aged £2 years are
vaccinated. The present study revealed a high
coverage (77%) of penicillin non-susceptible
isolates by this vaccine. Moreover, recent data
from the USA have shown that use of this
vaccine can be a powerful strategy for reducing
antibiotic resistance in a community [25]. How-
ever, the present study also found that a
signiﬁcant amount of penicillin resistance in
Germany was associated with serotype 19A, a
serotype that is covered only partially by the
seven-valent pneumococcal conjugate vaccine,
suggesting that the inclusion of serotype 19A
in future vaccine formulations is required.
In summary, the present study revealed a
signiﬁcant increase in antibiotic resistance among
IPD isolates from German children. MLST
proved to be a powerful tool for analysing the
molecular background to the development of
resistance, and for documenting the genetic
diversity of pneumococcal clones. Restricted
use of antibiotics and wider use of the seven-
valent pneumococcal conjugate vaccine may be
an effective approach for combating the future
spread of antibiotic resistance among S. pneumo-
niae strains in Germany.
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